Topical steroids available from Schering-Plough

Click here to download Adobe Acrobat

Schering-Plough has several topical steroids indicated for the treatment of eczema and other skin conditions:

Elocon®

Elocon®, containing the active ingredient mometasone furoate, is a potent synthetic topical corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of:

  • Psoriasis15,16
  • Atopic eczema15
  • Seborrhoeic dermatitis of the scalp16

Clinical trials have shown that, with a single daily dose, Elocon® produces more rapid relief of eczema17 and more effective relief of psoriasis18,19 than betamethasone valerate twice daily.

Elocon should not be used in children or on the face for more than 5 days.15,16

Elocon® has a safety profile comparable to hydrocortisone20, and is available in a range of presentations to suit different types of lesion:

  • Elocon® cream: 30g and 100g tubes15
  • Elocon® ointment for dry, lichenified or scaly areas: 30g and 100g tubes15
  • Elocon® lotion for psoriasis, eczema or dermatitis affecting the scalp: 30ml dropper bottles16

For more detailed information about Elocon®, click on one of the links below:

  • View the Elocon® cream Summary of Product Characteristics
  • View the Elocon® ointment Summary of Product Characteristics
  • View the Elocon® scalp lotion Summary of Product Characteristics
  • Download prescribing information about Elocon® cream/ointment
  • Download prescribing information about Elocon® scalp lotion
Diprosone®

For eczema and dermatitis: Diprosone® contains betamethasone dipropionate, a potent topical fluorinated corticosteroid offering rapid remission of symptoms and sustained efficacy against all types of eczema and dermatitis.21,22,23

For psoriasis: Diprosone® cream and ointment also treat certain forms of psoriasis including psoriasis of the scalp and hands and feet, but not widespread plaque psoriasis.21,22 Diprosone® lotion is available for the treatment of psoriasis of the scalp.23

Diprosone® is available in a range of presentations to suit different types of lesion:

  • Diprosone® cream for moist or weeping lesions21
  • Diprosone® ointment for dry, lichenified or scaly areas22
  • Diprosone® lotion for eczema, dermatitis or psoriasis affecting the scalp23

For more detailed information about Diprosone®, click on one of the links below:

  • View the Diprosone® cream Summary of Product Characteristics
  • View the Diprosone® ointment Summary of Product Characteristics
  • View the Diprosone® lotion Summary of Product Characteristics
  • Download prescribing information about Diprosone® cream/ointment
  • Download prescribing information about Diprosone® lotion
Diprosalic®

Diprosalic® contains a combination of betamethasone dipropionate, a potent topical fluorinated corticosteroid, and salicylic acid which, as a result of its descaling action, allows access to the dermis more rapidly than by applying steroids alone.24,25

Diprosalic® brings the benefits of the rapid sustained response seen with Diprosone® to the treatment of hyperkeratotic and dry corticosteroid-responsive dermatoses where the cornified epithelium may resist penetration of the steroid.24,25

Diprosalic® is available either as ointment or as scalp application.

For more detailed information about Diprosalic®, click on one of the links below:

  • View the Diprosalic® ointment Summary of Product Characteristics
  • View the Diprosalic® scalp application Summary of Product Characteristics
  • Download prescribing information for Diprosalic® ointment and scalp application
References:
  1. 15. Elocon cream and ointment SmPC
  2. 16. Elocon scalp lotion SmPC
  3. 17. Rajka G et al. Curr Ther Res 1993; 54(1):23-29
  4. 18. Rosenthal D, Duke E. Curr Ther Res 1988; 44(5): 790-801.
  5. 19. Vanderploeg DE et al. Acta Therapeutica 1989; 15: 145-152
  6. 20. Katz HI et al. Int. J Dermatol 1989; 28: 342-344
  7. 21. Diprosone cream SmPC
  8. 22. Diprosone ointment SmPC
  9. 23. Diprosone lotion SmPC
  10. 24. Diprosalic ointment SmPC
  11. 25. Diprosalic lotion SmPC

Date of preparation: June 2009 / Code: DIP/09-588